Neurocrine Biosciences Inc (NBIX) Stock Price & Analysis
Neurocrine Biosciences Inc (NBIX) rose 1.30% to USD 165.24 as of June 10, 2026 at 00:55 UTC, according to Nexqual real-time market data.
NBIX last closed at USD 163.12; the session ranged USD 160.88–166.43 on volume of 1,096,892 shares. Market capitalization is $16.61B, with a 52-week range of USD 122.14–169.57 (NMS). Source: Nexqual, June 10, 2026 at 00:55 UTC.
Key Statistics (as of June 10, 2026 at 00:55 UTC)
| Price | USD 165.24 |
|---|---|
| Change | ▲ 1.30% (up) |
| Previous Close | USD 163.12 |
| Open | USD 164.89 |
| Day Range | USD 160.88 – 166.43 |
| 52-Week Range | USD 122.14 – 169.57 |
| Volume | 1,096,892 shares |
| Market Cap | $16.61B |
| Exchange | NMS |
Technical Analysis (NBIX)
Nexqual's technical model rates NBIX "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:55 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 67.28 (neutral) |
| vs SMA50 | Above (USD 143.64) |
| MACD | 5.84 (positive) |
Analyst Ratings (NBIX)
Wall Street analysts rate NBIX "Strong Buy" based on 29 analysts, with a mean price target of USD 192.88 (range USD 144–250.65), per Nexqual as of June 10, 2026 at 00:55 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 192.88 |
| High Target | USD 250.65 |
| Low Target | USD 144 |
| Buy / Hold / Sell | 25 / 4 / 0 |
Earnings (NBIX)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 2.11 |
| Revenue Estimate | $864.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.94 vs est 1.7 ▲ beat |
| 2025-12-31 | USD 1.88 vs est 2.3 ▼ miss |
| 2025-09-30 | USD 2.17 vs est 2.07 ▲ beat |
| 2025-06-30 | USD 1.65 vs est 1.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financials & Fundamentals (NBIX)
| Total Revenue | $3.10B |
|---|---|
| Revenue Growth (YoY) | +42.20% |
| Gross Margin | +64.37% |
| Operating Margin | +22.84% |
| Profit Margin | +21.55% |
| ROE | +22.50% |
| Debt / Equity | 13.6 |
| Current Ratio | 2.93 |
| Total Cash | $1.32B |
| Total Debt | $463.50M |
| Free Cash Flow | $590.55M |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financial Health Score (NBIX)
Nexqual rates Neurocrine Biosciences Inc's overall financial health "Strong" across five dimensions, as of June 10, 2026 at 00:55 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 23% |
| Balance Sheet | Strong — $1.32B cash vs $464M debt, net cash position |
| Cash Flow | Strong — FCF $591M, 21% margin |
| Efficiency | Strong — ROE 23%, ROA 11.6% |
Ownership (NBIX)
| Insider Ownership | +1.08% |
|---|---|
| Institutional Ownership | +103.73% |
| Shares Outstanding | 100.55M |
| Float | 99.29M |
| Short % of Float | +7.16% |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Leadership (NBIX)
Neurocrine Biosciences Inc is led by Kyle W. Gano (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:55 UTC.
| President, CEO & Director | Kyle W. Gano (age 52) |
|---|---|
| Chief Financial Officer | Matthew C. Abernethy (age 45) |
| Chief Scientific Officer | Jude Onyia (age 61) |
| Vice President of Investor Relations | Todd Tushla |
Major Backers & Investors (NBIX)
Notable institutional backers of Neurocrine Biosciences Inc include Dodge & Cox Inc., JPMorgan, AQR Capital Management, LLC, according to Nexqual as of June 10, 2026 at 00:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 9.37% |
| JPMorgan | 6.61% |
| AQR Capital Management, LLC | 4.91% |
| Two Sigma Investments, LP | 3.04% |
| Renaissance Technologies | 2.41% |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.99% |
| BlackRock | 16.68% |
| State Street | 5.09% |
| Geode Capital | 2.12% |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
From Neurocrine Biosciences Inc's Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- By harnessing both novel validated mechanisms and our proprietary platforms, we aim to launch, on average, approximately one new medicine every two years, driving long-term value for patients and shareholders. 5 The following chart summarizes select clinical development programs.
- Our confidence in this approach is bolstered by our internal know-how of over 30 years studying CRF biology and the success of our first CRF program in CAH. 8 Research and Discovery Engine and Ongoing Innovation Underpinning all our programs is a reinvigorated research and discovery engine that we have built to be both innovative and efficient.
- This focused distribution model allows us to closely manage product supply and support services.
- We believe our outsourced manufacturing strategy enables us to direct our financial resources to maximize our commercial opportunities with INGREZZA and CRENESSITY, invest in our internal research and development programs, and expand our clinical pipeline through business development opportunities.
Partnerships
- Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
| ALKS | Alkermes plc | USD 44.29 | ▲ 3.48% |
| INCY | Incyte Corporation | USD 103.23 | ▲ 0.83% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 57.91 | ▲ 2.01% |
| UTHR | United Therapeutics Corporation | USD 553.14 | ▲ 0.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:55 UTC. This page is informational and not investment advice.